Tuesday, November 2, 2021

NICE recommends Alexion’s PNH treatment Ultomiris

The National Institute for Health and Care Excellence (NICE) has recommended Alexion’s C5 complement inhibitor Ultomiris for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Specifically, NICE has backed the use of Ultomiris (ravulizumab) in the NHS for the treatment of PNH in adult patients with haemolysis and clinical symptoms suggesting high disease activity, or for those whose disease is clinically stable after taking Soliris (eculizumab) for six months.

Data from a pivotal Phase III study showed that Ultomiris was non-inferior to Soliris in complement inhibitor treatment-naïve patients with PNH, based on the co-primary endpoints of transfusion avoidance and normalisation of lactate dehydrogenase (LDH) levels.

“We are delighted at the recommendation from NICE, meaning we will be able to offer ravulizumab as a new treatment option to adult patients with PNH across the UK, helping to improve their overall quality of life,” said Sean Richardson, Alexion general manager, UK & Ireland.

“We believe ravulizumab will become the new standard of care for patients with PNH by providing immediate and complete C5 inhibition, sustained throughout the eight-week dosing interval,” he added.

PNH is an ultra-rare blood disorder that can affect men and women with no prior warning and has an average age of onset in the early 30s.

Patients living with PNH experience complement-mediated destruction of red blood cells – haemolysis – and also face risks of blood clots, which can result in organ damage and premature death.

Often, PNH is not immediately recognised, with delays in the diagnosis of this condition ranging from one to over five years.

“Ravulizumab is as effective as the previous standard of care, eculizumab, with a similar safety profile, but with a longer-acting formulation,” said Peter Hillmen, professor of experimental haematology at the University of Leeds and honorary consultant in clinical haematology at Leeds Teaching Hospitals NHS Trust.

“Patients with PNH will now only require infusions every 8 weeks rather than every 2 weeks which will have a major impact on their quality of life,” he added.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...